[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"valvular-heart-disease-patients\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:valvular-heart-disease-patients":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100627565","cardionetpol-national-registry-of-carcinoid-heart-disease-100627565",false,"NCT07450287","CardioNETPOL National Registry of Carcinoid Heart Disease","Carcinoid Heart Disease National Registry of Poland","CardioNETPOL","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Confirmed diagnosis of a neuroendocrine tumor consistent with carcinoid heart disease.\n* Echocardiographic evidence of at least moderate valvular disease associated with endocardial fibrosis.\n* Elevated NT-proBNP levels (\\>260 ng\u002FL) consistent with cardiac dysfunction.\n* Availability of relevant clinical, echocardiographic, and laboratory data.\n* For patients who underwent cardiac surgery, histopathological confirmation of carcinoid-related cardiac tissue (if available).\n* Ability to provide informed consent for participation in the registry (or waiver as per local ethics approval for retrospective data).\n\nExclusion Criteria:\n\n* Patients with insufficient clinical or imaging data to confirm carcinoid heart disease.\n* Presence of other primary cardiac conditions causing significant valvular disease unrelated to carcinoid syndrome (e.g., rheumatic heart disease, congenital valve disease)\n* Active participation in interventional clinical trials that would conflict with registry data collection\n* Patients younger than 18 years","ALL","18 Years",{"count":20,"type":21},120,"ESTIMATED","OBSERVATIONAL","Carcinoid tumors are neuroendocrine tumors (NETs), most commonly originating from the gastrointestinal tract, that may secrete bioactive substances such as serotonin. Persistent exposure to these mediators can lead to carcinoid syndrome and, in up to 50% of patients, carcinoid heart disease (CHD). CHD is characterized by fibrotic degeneration of cardiac valves, predominantly right-sided, resulting in progressive valvular dysfunction and a significant increase in mortality.\n\nThe mechanisms underlying selective cardiac involvement and predictors of disease progression remain incompletely understood. In addition, optimal timing and selection of surgical versus transcatheter valve interventions, particularly in high-risk patients, require further clarification.\n\nThis multicenter, retrospective observational registry aims to identify and characterize patients with carcinoid heart disease and at least moderate valvular involvement. CHD is defined by confirmed neuroendocrine tumor, echocardiographic evidence of ≥ moderate valvular disease with features of fibrosis, elevated NT-proBNP (\\>260 ng\u002FL), and histopathological confirmation when available.\n\nApproximately 100-120 consecutive patients will be enrolled over 12 months. Standardized data collection will include detailed echocardiographic assessment, demographic and clinical characteristics, cardiovascular risk factors, comorbidities, tumor features, oncological treatment history, and cardiac management strategies.\n\nThe primary objective is to describe the clinical profile and management of patients with CHD in a real-world multicenter setting. Secondary objectives include identifying factors associated with advanced valvular dysfunction and evaluating eligibility and outcomes of transcatheter valve therapies. The registry is expected to improve risk stratification and support clinical decision-making in carcinoid heart disease.",[25,26,27,28],"Carcinoid Heart Disease","Neuroendocrine Tumors","Carcinoid Syndrome","Valvular Heart Disease Patients",[25,30,27,31,32,33,34,35],"Neuroendocrine Tumor","Valvular Heart Disease","Transcatheter Tricuspid Valve Intervention","Observational Study","Multicenter Registry","Right-Sided Heart Failure","NOT_YET_RECRUITING","2026-02-27",{"date":39,"type":40},"2026-03-04","ACTUAL",{"date":42,"type":21},"2026-06-01",{"date":44,"type":21},"2027-06-01",{"name":46,"class":47},"National Institute of Cardiology, Warsaw, Poland","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":48},"100594750","the-valve-ai-trial-100594750","NCT07023510","The VALVE-AI Trial","VALidation of Screening Valvular Heart Disease Using Electrocardiogram Powered by Artificial Intelligence: A Randomized Controlled Trial","Inclusion Criteria:\n\n* At least one 12-lead ECG within 1 year\n* Age 60-85 years of age\n\nExclusion Criteria:\n\n* Documented echocardiography within 3 years before indexed ECG\n* Any known valvular heart disease\n* History of any valvular surgery\n* Post-heart transplant","60 Years","85 Years",{"count":59,"type":21},8648,"INTERVENTIONAL",[62],"NA","The goal of this clinical trial is to learn if an artificial intelligence-powered electrocardiogram (AI-ECG) can help detect moderate or severe valvular heart diseases (VHD) in adults. The main question it aims to answer is:\n\n．Can AI-ECG screening identify patients with significant heart valve diseases who may benefit from early echocardiography? Researchers will compare the rate of moderate or severe VHD detection between the experimental group and the control group to see if AI-ECG improve the detection rate of significant VHD.\n\nParticipants will:\n\n* Be classified as high- or low-risk for VHD using an AI-ECG system\n* In the experimental group, high-risk participants will receive echocardiography based on AI-ECG results\n* In the control group, usual clinical care will be provided without routine echocardiography for AI-ECG high-risk results.",[28],"RECRUITING","2025-06-23",{"date":68,"type":40},"2025-06-26",{"date":70,"type":21},"2025-07-01",{"date":72,"type":21},"2026-07-01",{"name":74,"class":47},"National Defense Medical Center, Taiwan"]